CytoMed Therapeutics Stock (NASDAQ: GDTC)

Dernières nouvelles pour CytoMed Therapeutics (NASDAQ:GDTC) Stock

CytoMed Therapeutics

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics Ltd

<h3>Gainers</h3>
<ul>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock moved upwards by 116.2% to $8.8 during Monday's pre-market session. The market value of their outstanding shares is at $5.8 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares moved upwards by 70.57% to $0.23. The company's market cap stands at $7.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) shares rose 25.0% to $3.6. The market value of their outstanding shares is at $143.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) stock moved upwards by 22.89% to $0.74. The market value of their outstanding shares is at $1.5 million. </li>
<li>Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) stock rose 17.05% to $5.56. The company's market cap stands at $309.2 million. </li>
<li>Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) shares increased by 15.83% to $122.51. The market value of their outstanding shares is at $5.9 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares decreased by 61.5% to $3.0 during Monday's pre-market session. The company's market cap stands at $182.5 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock fell 14.6% to $2.4. The company's market cap stands at $27.6 million. </li>
<li>ImmuCell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICCC#NASDAQ">ICCC</a>) stock decreased by 11.94% to $4.5. The company's market cap stands at $40.1 million. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares declined by 10.99% to $2.27. The company's market cap stands at $63.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) stock fell 10.93% to $1.06. The market value of their outstanding shares is at $34.7 million. </li>
<li>Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) stock declined by 10.18% to $0.1. The company's market cap stands at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AXSM

BACK

BDRX

CYTH

FHTX

GDTC

ICCC

MBOT

OCEA

OMGA

PLRX

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

News

CytoMed Therapeutics Chairman Sends Letter To Shareholders; Intends To Implement Radical Revenue-generating Methods

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares increased by 81.0% to $2.28 during Monday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 36.93% to $7.6. The company's market cap stands at $464.9 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares rose 35.56% to $128.61. The company's market cap stands at $13.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 32.73% to $0.16. The market value of their outstanding shares is at $2.4 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 27.53% to $3.52. The market value of their outstanding shares is at $40.6 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 26.03% to $3.34. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 14.7% to $7.0 during Monday's pre-market session. The company's market cap stands at $1.1 billion. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares declined by 13.69% to $0.82. The market value of their outstanding shares is at $9.8 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares decreased by 12.7% to $29.43. The market value of their outstanding shares is at $105.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock fell 12.49% to $0.61. The market value of their outstanding shares is at $2.9 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock declined by 12.21% to $5.25. The company's market cap stands at $303.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock declined by 12.11% to $0.71. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ALGS

ATPC

GCTK

GTBP

INDP

ITCI

NAYA

OCUL

SAGE

Shares of Inari Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) rose sharply in today's pre-market trading after Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) announced plans to acquire the company for <a href="https://www.benzinga.com/quote/NARI/news">$80 per share in cash.</a>
Inari Medical shares jumped 21.2% to $78.79 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MultiSensor AI Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) gained 101% to $4.02 in pre-market trading after the company announced management appointments.</li>
<li>Algorhythm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) gained 86.3% to $0.2697 in pre-market trading after surging 30% on Monday.</li>
<li>XTI Aerospace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) rose 61.9% to $0.1425 in pre-market trading after gaining around 113% on Monday.</li>
<li>Healthy Choice Wellness Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWC#NASDAQ">HCWC</a>) rose 51.5% to $1.47 in pre-market trading after falling 12% on Monday. The company reported fourth-quarter financial results.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) rose 47.1% to $9.59 in pre-market trading after the company partnered with Continental and NVIDIA to launch next-generation driverless trucks by 2027.</li>
<li>DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>) gained 34.1% to $2.63 in pre-market trading.</li>
<li>Getty Images Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) gained 30.8% to $3.36 in pre-market trading. Getty Images and Shutterstock announced a merger agreement for $3.7 billion.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 17.3% to $0.0848 in pre-market trading. Conduit Pharmaceuticals, last month, announced it entered an agreement with Sarborg to leverage AI and its cybernetics platform to evaluate key deliverables across multiple areas of operations.</li>
<li>Syra Health Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) gained 16.3% to $0.5700 in pre-market trading after gaining 9% on Monday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Boxlight Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOXL#NASDAQ">BOXL</a>) fell 25.6% to $1.25 in pre-market trading after jumping 265% on Monday.</li>
<li>Splash Beverage Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBEV#NASDAQ">SBEV</a>) fell 21.5% to $0.2120 in pre-market trading after jumping around 13% on Monday.</li>
<li>CytoMed Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) shares fell 20.8% to $2.72 in pre-market trading. CytoMed Therapeutics announced it entered into a business and research collaboration agreement with Mumbai-based SunAct Cancer Institute.</li>
<li>Babcock &amp; Wilcox Enterprises, (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWNB#NYSE">BWNB</a>) fell 19.1% to $17.00 in today's pre-market trading.</li>
<li>Gold Resource Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GORO#NYSE">GORO</a>) fell 17.7% to $0.1880 in pre-market trading after announcing a $2.5 million registered direct offering.</li>
<li>Kuke Music Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KUKE#NYSE">KUKE</a>) shares fell 17.2% to $0.5549 in pre-market trading.</li>
<li>Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) dipped 15.4% to $2.95 in pre-market trading. ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.</li>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) shares tumbled 13.2% to $7.00 in pre-market trading.</li>
<li>BP Prudhoe Bay Royalty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BPT#NYSE">BPT</a>) shares dipped 12.1% to $0.6789 in pre-market trading as the company announced no unit payment for the fourth quarter.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) declined 8.9% to $11.70 in pre-market trading after dipping more than 10% on Monday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42838883/rpm-international-cal-maine-foods-and-3-stocks-to-watch-heading-into-tuesday">RPM International, Cal-Maine Foods And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>

BOXL

BWNB

COGT

DATS

GETY

GORO

HCWC

KUKE

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NARI

RIME

SBEV

SLRN

SYRA

XCUR

XTIA

Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket

On Monday, CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock is down 6.35% at $3.23 at last check Monday.
The Singapore-based clinical-stage biopharmaceutical entered into a five-year Business &amp; Research Collaboration Agreement (BRCA) with India-based SunAct Cancer Institute Private.
The BRCA will explore the safety, tolerability, potency, and efficacy of CytoMed&#8217;s proprietary allogeneic gamma delta T cells for various cancers (including solid tumors). The human clinical research trial includes a Phase 2 investigator-<a href="https://www.benzinga.com/pressreleases/25/01/g42810193/cytomed-therapeutics-signs-business-research-collaboration-agreement-with-indias-sunact-cancer-ins" target="_blank" rel="noreferrer noopener">initiated trial in India</a>.
CytoMed and SunAct will be the joint sponsors of the clinical trial.
&#8220;Initiating this research and undertaking the accelerated Clinical Trial in the form of a combined Phase 1 and Phase 2 Clinical Trial targets not just the safety and efficacy of the therapeutic application and intervention of allogeneic gamma delta T Cells in the treatment of solid cancers but also expedites the gathering of information and data on the initial safety, preliminary efficacy and optimal dosing. We expect to identify the types of cancers the therapy will work for, including the side effects of the same if any and how we might manage them,&#8221; said Dr Vijay Patil.
CytoMed chairman Peter Choo called the collaboration with SunAct &#8220;timely.&#8221; 
According to the BRCA, CytoMed will provide scientific and technical assistance in planning and conducting the clinical trial.
CytoMed will also be responsible for manufacturing the allogeneic gamma delta T cells as the investigational product.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42812207/arcelormittal-south-africa-to-cut-3500-jobs-amid-economic-struggles" target="_blank" rel="noreferrer noopener">ArcelorMittal South Africa To Cut 3,500 Jobs Amid Economic Struggles</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Trading Ideas

General

Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor

CytoMed Therapeutics shares are trading higher after the company announced it entered into a business and research collaboration agreement with Mumbai-based SunAct Cancer Institute.

The collaboration forms a collaborative effort between CytoMed and SunAct to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for the treatment of various cancers (including solid tumors) in human subjects through clinical research, including a Phase 2 investigator-initiated trial in India.&nbsp;
CytoMed and SunAct will be the joint sponsors of the Clinical Trial.

Contracts

CytoMed Therapeutics Has Entered Into A Business & Research Collaboration Agreement With Mumbai-Based SunAct Cancer Institute Private

CytoMed Therapeutics Has Dosed The First Patient In Its First-In-Human Phase I Dose-Escalation ANGELICA Trial Of Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Gamma Delta T Cells In Patients With Advanced Solid Tumors Or Hematological Malignancies

Benchmark analyst Bruce Jackson reiterates CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) with a Speculative Buy and maintains $5 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Speculative Buy on CytoMed Therapeutics, Maintains $5 Price Target

<ul>
<li>The acquisition includes (i) a cord blood banking licence issued by Malaysia's Ministry of Health, (ii) cryopreservation equipment with more than 12,000 cord blood units, and (iii) two freehold real estate properties totalling 189 square metres in which the operation is situated.</li>
<li>This acquisition will expand CytoMed's strategy in cell therapies as it now has access to rare and precious naïve cord blood donated for research and development. There are abundant clinical publications and evidence that cord blood offers a wide range of opportunities in the fields of regenerative medicine and aging diseases, including auto-immune diseases. This new biotechnology arm will be undertaken through CytoMed's subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.</li>
</ul>

CytoMed Therapeutics Has Acquired The License And Certain Assets Of Cellsafe International, A Malaysian Cord Blood Bank, Deal Terms Were Not Disclosed

WIIM

CytoMed Therapeutics shares are trading higher after the company announced that its subsidiary, IPSC Depository, acquired the license and certain assets of Cellsafe International for approximately $490,000 to be funded from internal cash resources.

Cytomed Therapeutics, Through Its Wholly Owned Subsidiary, IPSC Depository Acquired The Licence And Certain Assets Of Cellsafe International For A Cash Consideration Of About RM 2.3M Or $490,000 To Be Funded From Internal Cash Resources

CytoMed Therapeutics Diversifies Into Regenerative Medicine After Research Collaboration With Singapore's Sengkang General Hospital

CytoMed Therapeutics Has Obtained Board Approval To Launch, Pilot Program To Isolate And Cryo-Store Peripheral Blood Mononuclear Cells For And As A Reward To Loyal Shareholders Of CytoMed On Complimentary Basis, The Program Will Commence On June 1, 2024

<a href="https://www.globenewswire.com/Tracker?data=Z3I3CabDDyTI5w5M__vI-QSXWV8XNAhKM46cTCP48WXblNKcBdRLdVTLWXb_HmB-EDP59YSnl6sJ2_MF_36kUxr7nrcVLqH-OTrYQzOyVYs=" target="_blank">CytoMed Therapeutics Limited</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) (&quot;CytoMed&quot; or &quot;Company&quot;), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement (&quot;RCA&quot;) with Sengkang General Hospital Pte Ltd (&quot;SKH&quot;), a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (&quot;UC-MSCs&quot;) to treat cartilage injury. This injectable therapy will be implemented&nbsp;in vivo&nbsp;to support the application and commencement of a proposed Phase 1 clinical trial in Singapore, and is anticipated to complete within two years.

CytoMed Therapeutics Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

<h3>Gainers</h3>
<ul>
<li>KalVista Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) stock moved upwards by 11.0% to $15.99 during Wednesday's after-market session. The market value of their outstanding shares is at $552.5 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) stock increased by 9.25% to $0.25. The company's market cap stands at $3.0 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock rose 7.5% to $2.58. The market value of their outstanding shares is at $29.7 million. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock rose 7.12% to $0.85. The market value of their outstanding shares is at $10.6 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 6.66% to $1.68. The company's market cap stands at $6.1 million. </li>
<li>Cidara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) stock increased by 6.55% to $0.72. The market value of their outstanding shares is at $65.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) stock declined by 8.6% to $3.6 during Wednesday's after-market session. The market value of their outstanding shares is at $521.1 million. The company's, Q4 earnings came out today. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock fell 8.11% to $1.7. The market value of their outstanding shares is at $61.2 million. As per the news, the Q3 earnings report came out 2 days ago. </li>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares fell 6.93% to $1.21. The company's market cap stands at $2.9 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares decreased by 6.76% to $0.17. The company's market cap stands at $4.7 million. </li>
<li>Panbela Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBLA#NASDAQ">PBLA</a>) stock decreased by 6.62% to $1.27. The company's market cap stands at $4.4 million. </li>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) stock declined by 6.57% to $0.18. The market value of their outstanding shares is at $5.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADPT

AFIB

AZTR

CDTX

KALV

OTRK

PBLA

TNON

VCNX

XAIR

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>NanoString Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSTG#NASDAQ">NSTG</a>) stock moved upwards by 26.9% to $0.15 during Friday's pre-market session. The company's market cap stands at $7.0 million. </li>
<li>TC BioPharm (Holdings) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>) stock rose 21.81% to $1.34. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock increased by 21.32% to $1.74. The company's market cap stands at $57.6 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) shares moved upwards by 20.5% to $2.41. The market value of their outstanding shares is at $118.1 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock rose 14.28% to $2.56. The market value of their outstanding shares is at $29.5 million. </li>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) stock increased by 11.76% to $0.19. The company's market cap stands at $5.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Synlogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBX#NASDAQ">SYBX</a>) shares decreased by 52.2% to $1.65 during Friday's pre-market session. The company's market cap stands at $15.1 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares decreased by 35.47% to $2.42. The market value of their outstanding shares is at $72.4 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) stock declined by 19.07% to $0.52. The company's market cap stands at $1.7 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock declined by 16.71% to $4.04. The company's market cap stands at $25.9 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 12.08% to $0.12. The market value of their outstanding shares is at $2.9 million. </li>
<li>Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) stock fell 11.36% to $2.03. The company's market cap stands at $113.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTAI

CRVS

DSGN

EVOK

NSTG

OKYO

SYBX

TCBP

12 Health Care Stocks Moving In Friday's Pre-Market Session

Shares of The Container Store Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tcs#NYSE">TCS</a>) shares fell sharply during Wednesday&rsquo;s session following weak quarterly results.
Container Store Group posted adjusted loss of 8 cents per share, compared to market expectations for a loss of 5 cents per share. The company&rsquo;s quarterly sales came in at $214.90 million versus estimates of $220.72 million.
Container Store Group shares dipped 22.7% to $1.3150 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>MicroCloud Hologram Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/holo#NASDAQ">HOLO</a>) shares jumped 400% to $7.51. The company announced it planned to join the Communications Industry Association. HOLO intends to join the Communications Industry Association to foster information technology innovation.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smx#NASDAQ">SMX</a>) shares climbed 138% to $0.5528.</li>
<li>Glatfelter Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/glt#NYSE">GLT</a>) climbed 68.8% to $2.1450 after the company and Berry Global announced they entered into definitive agreements for Berry to spin-off and merge the majority of its Health, Hygiene and Specialties segment to include its Global Nonwovens and Films business with Glatfelter.</li>
<li>MariaDB plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mrdb#NYSE">MRDB</a>) gained 57% to $0.3782 after jumping more than 26% on Tuesday.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/thmo#NASDAQ">THMO</a>) climbed 37.7% to $0.8101.</li>
<li>Recon Technology, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rcon#NASDAQ">RCON</a>) rose 33.3% to $0.1934.</li>
<li>Ault Alliance, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ault#NYSE">AULT</a>) surged 28.1% to $0.4549. Ault Alliance said it determined not to pursue new acquisitions during 2024, though it may continue to make strategic investments.</li>
<li>Luokung Technology Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lkco#NASDAQ">LKCO</a>) gained 27.4% to $0.6269.</li>
<li>MicroAlgo Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mlgo#NASDAQ">MLGO</a>) rose 27% to $0.4939.</li>
<li>Aviat Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avnw#NASDAQ">AVNW</a>) surged 23.7% to $37.20 after the company reported better-than-expected second-quarter financial results and issued FY24 revenue guidance above estimates.</li>
<li>Jianpu Technology Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jt#NYSE">JT</a>) gained 18.5% to $0.7584.</li>
<li>Enphase Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/enph#NASDAQ">ENPH</a>) rose 17.7% to $118.36 after the company reported quarterly financial results.</li>
<li>Sonos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sono#NASDAQ">SONO</a>) gained 17.6% to $19.36 after the company reported better-than-expected quarterly financial results.</li>
<li>XPO, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpo#NYSE">XPO</a>) climbed 16.6% to $114.34 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Cirrus Logic, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crus#NASDAQ">CRUS</a>) gained 15.1% to $90.28 after the company reported better-than-expected quarterly financial results.</li>
<li>Green Plains Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gpre#NASDAQ">GPRE</a>) climbed 14.6% to $22.94 following quarterly results.</li>
<li>Hitek Global Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hkit#NASDAQ">HKIT</a>) rose 14.1% to $0.81.</li>
<li>Griffon Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gff#NYSE">GFF</a>) gained 13.8% to $68.55 following upbeat results.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) rose 13.3% to $14.78. Regenxbio has completed enrollment at dose level 2 and reported additional interim safety and efficacy in Phase 1/2 AFFINITY DUCHENNE trial of Rgx-202 in patients with Duchenne Muscular Dystrophy ages 4 to11 years old.</li>
<li>O-I Glass, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/oi#NYSE">OI</a>) climbed 12.7% to $16.19 following upbeat results.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulcc#NASDAQ">ULCC</a>) rose 11.3% to $6.93. Frontier reported fourth-quarter financial results and issued guidance.</li>
<li>Silicon Laboratories Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slab#NASDAQ">SLAB</a>) jumped 11.1% to $131.43 after the company reported better-than-expected quarterly financial results and issued guidance.</li>
<li>Griid Infrastructure Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grdi#NASDAQ">GRDI</a>) gained 10.9% to $2.35 after gaining over 4% on Tuesday.</li>
<li>Emerson Electric Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/emr#NYSE">EMR</a>) climbed 10.8% to $104.44 after the company reported better-than-expected quarterly earnings and raised FY24 outlook.</li>
<li>Yum China Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yumc#NYSE">YUMC</a>) shares rose 9.9% to $41.14 after the company reported fourth-quarter financial results and increased its dividend.</li>
<li>IHS Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ihs#NYSE">IHS</a>) gained 8.1% to $3.1250.</li>
<li>Fortinet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ftnt#NASDAQ">FTNT</a>) rose 4% to $70.13 after the company reported better-than-expected fourth-quarter financial results and issued guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Snap Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snap#NYSE">SNAP</a>) shares dipped 35.2% to $11.30 after the company reported mixed fourth-quarter results.</li>
<li>Sunworks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sunw#NASDAQ">SUNW</a>) shares fell 29.1% to $0.0617. Sunworks shares dipped 58% on Tuesday after the company announced it ceased operations and filed voluntary petitions for relief under the provisions of Chapter 7 of Title 11 of the United States Code.</li>
<li>CytoMed Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdtc#NASDAQ">GDTC</a>) dipped 26.7% to $2.25.</li>
<li>fuboTV Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fubo#NYSE">FUBO</a>) shares fell 25.7% to $1.8650 after gaining around 4% on Tuesday.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) tumbled 23.6% to $2.62.</li>
<li>The E.W. Scripps Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ssp#NASDAQ">SSP</a>) fell 22.8% to $5.74.</li>
<li>MedAvail Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdvl#NASDAQ">MDVL</a>) shares declined 20.4% to $2.61 after jumping 92% on Tuesday.</li>
<li>Triumph Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tgi#NYSE">TGI</a>) fell 18.8% to $13.35 after the company reported below-consensus third-quarter results and cut the FY24 outlook.</li>
<li>Perion Network Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/peri#NASDAQ">PERI</a>) fell 18.6% to $24.00 after the company issued worse-than-expected FY24 outlook.</li>
<li>ePlus inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plus#NASDAQ">PLUS</a>) shares declined 17.6% to $64.50 after the company reported worse-than-expected third-quarter results.</li>
<li>The Hain Celestial Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hain#NASDAQ">HAIN</a>) fell 16.9% to $9.42 after the company reported worse-than-expected quarterly revenue results.</li>
<li>Soho House &amp; Co Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/shco#NYSE">SHCO</a>) fell 15.9% to $5.20.</li>
<li>KKR Real Estate Finance Trust Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kref#NYSE">KREF</a>) shares dipped 14.3% to $10.09 following fourth-quarter results.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aosl#NASDAQ">AOSL</a>) fell 14.1% to $22.11. The company reported second-quarter financial results and issued revenue guidance.</li>
<li>New York Community Bancorp, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NYSE">NYCB</a>) shares declined 12.8% to $3.6599. Fitch downgraded NYCB&rsquo;s long-term credit rating to one notch above non-investment grade at BBB-. Moody&rsquo;s downgraded NYCB&#39;s debt rating from Baa3 to Ba2.</li>
<li>Viasat, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vsat#NASDAQ">VSAT</a>) fell 12.7% to $19.88 after the company reported quarerly financial results.</li>
<li>V.F. Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vfc#NYSE">VFC</a>) shares declined 12.2% to $14.88 after the company reported worse-than-expected third-quarter financial results.</li>
<li>Vestis Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vsts#NYSE">VSTS</a>) fell 10.2% to $20.03 after the company reported worse-than-expected first-quarter sales results.</li>
<li>Rekor Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rekr#NASDAQ">REKR</a>) fell 9.5% to $2.7150 after the company announced the launch of a proposed follow-on public offering of common stock.</li>
<li>Berry Global Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bery#NYSE">BERY</a>) fell 9.2% to $58.35 after the company reported below-consensus first-quarter FY24 results and disclosed a deal for a tax-free spin-off and merger of Berry&#39;s Health.</li>
<li>Valley National Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vly#NASDAQ">VLY</a>) declined 8.3% to $7.49.</li>
<li>ADDvantage Technologies Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aey#NASDAQ">AEY</a>) fell 6.6% to $0.5790 after surging 77% on Tuesday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/36983037/mckesson-earnings-are-imminent-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate"> McKesson Earnings Are Imminent; Here Are The Recent Forecast Changes From Wall Street&#39;s Most Accurate Analysts</a>

Penny Stocks

Small Cap

Intraday Update

Markets

AOSL

AULT

AVNW

BERY

CRUS

ENPH

FTNT

FUBO

GPRE

GRDI

HAIN

HKIT

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

KREF

LKCO

MDVL

MLGO

MRDB

NYCB

PERI

PLUS

RCON

REKR

RGNX

SHCO

SLAB

SNAP

SONO

SUNW

THMO

ULCC

VLCN

VSAT

VSTS

YUMC

Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) stock moved upwards by 39.0% to $0.86 during Wednesday's regular session. The market value of their outstanding shares is at $2.7 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) shares increased by 21.51% to $1.06. The company's market cap stands at $22.9 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock rose 13.77% to $12.1. The company's market cap stands at $288.1 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares rose 13.48% to $4.88. The company's market cap stands at $120.8 million. </li>
<li>FibroGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGEN#NASDAQ">FGEN</a>) shares increased by 12.87% to $2.16. The market value of their outstanding shares is at $212.0 million. </li>
<li>Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) stock increased by 12.78% to $0.98. The company's market cap stands at $484.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock declined by 29.3% to $2.17 during Wednesday's regular session. The market value of their outstanding shares is at $25.0 million. </li>
<li>Biolase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOL#NASDAQ">BIOL</a>) stock fell 25.69% to $0.38. The market value of their outstanding shares is at $1.3 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock fell 18.69% to $3.09. The company's market cap stands at $29.6 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock declined by 18.26% to $0.73. The company's market cap stands at $1.2 million. </li>
<li>Cingulate (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) shares declined by 17.04% to $1.07. The company's market cap stands at $1.5 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 15.52% to $0.8. The company's market cap stands at $13.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABEO

BFRI

BIOL

CATX

CING

COSM

ELTX

FEMY

FGEN

PEPG

12 Health Care Stocks Moving In Wednesday's Intraday Session

Press Releases

Presenting on the Emerging Growth Conference 74 Day 2 on August 22 Register Now

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

Earnings

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank

CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant

Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies

CytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India

CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders

CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates

Comments

CytoMed Therapeutics

Actualités

Dernières nouvelles pour CytoMed Therapeutics (NASDAQ:GDTC) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL